Premier Statement on Trump’s Executive Order on Restoring Robust Domestic Manufacturing for Prescription Drugs

By Soumi Saha, Premier Senior Vice President, Government Affairs, Premier Inc.

Today’s Executive Order signals growing momentum behind a goal Premier has been spotlighting for years: strengthening the healthcare supply chain starts with prioritizing domestic manufacturing.

Premier has consistently called for a comprehensive approach—including accelerating Food and Drug Administration (FDA) approvals for U.S.-based facilities that manufacture critical drugs and medical supplies. The protracted timeline for bringing a new domestic facility online and retooling an existing one is incompatible with the urgent public health challenges we face. Creating an expedited pathway for domestically manufactured products is a critical step toward building a more resilient, responsive and secure healthcare supply chain.

But this can’t be a one-policy solution. Real resilience is built like a braided rope—stronger with multiple strands. As we told the Department of Commerce today, alongside faster approvals, we need targeted tax incentives, fair reimbursement and trusted trade partnerships for near-shoring. Only with this kind of multi-pronged strategy can we build the strong domestic foundation our healthcare system—and patients—deserve.